Influência de doses e de duas fontes de potássio no sistema radicular do milho e na condutividade elétrica no solo

Atualmente vários programas de fertilização recomendam aplicação de altas doses de potássio, com cloreto de potássio (KCl) como principal fonte, apresentando alto poder salino, existindo alternativas de adubação potássica que podem apresentar menor efeito no solo. O presente trabalho teve como objetivo avaliar o efeito de diferentes doses de KCl e K-UP® no sistema radicular do milho e na condutividade elétrica no solo. O experimento foi conduzido em ambiente protegido no município de Minga Guazú, Departamento de Alto Paraná, Paraguai, no período de janeiro de 2016. Foi utilizado o delineamento fatorial inteiramente casualizado, envolvendo duas fontes de K, quatro doses, uma localização do fertilizante em relação às sementes e quatro repetições. As doses consistiram em equivalentes a 0, 50, 100 e 150 kg ha-1 de K2O, posicionadas lateralmente a 0,03 m da linha de semeadura. O solo foi acondicionado em caixas plásticas com 0,40 m de comprimento x 0,20 m de largura x 0,13 m de altura, e procedeu-se a semeadura do milho e adição do KCl e K-UP®. A umidade do solo mantida em 80% do teor de água na capacidade de campo desde a semeadura até germinação. Em cada tratamento foi avaliado a massa seca de raízes e condutividade elétrica do solo. Os resultados mostram que indiferente das fontes de K utilizada estas causam aumento na condutividade elétrica do solo. O K-UP® obteve os menores valores de condutividade elétrica e com o aumento da dose não ocorreu maior decréscimo na massa seca da raiz diferente do observado em relação ao KCl

Diferentes dosis de yeso agrícola y su efecto en el cultivo de soja

El yeso agrícola es una de las principales fuentes de S, utilizado como fertilizante o como acondicionador/corrector de suelo, con efectos en algunas propiedades químicas y físicas del suelo, principalmente luego de varios años de uso, acompañados de incrementos en las cosechas de cultivos. Este trabajo tuvo como objetivo determinar el efecto de la aplicación de yeso agrícola en el cultivo de soja.Consejo Nacional de Ciencia y Tecnología (CONACYT)Programa Paraguayo para el Desarrollo de la Ciencia y Tecnología (PROCIENCIA), Proyectos de investigación y desarroll

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after cessation of daily TPE. RESULTS Thirty-one patients (placebo, n = 28; caplacizumab, n = 3) had an exacerbation during double-blind treatment. Twenty-eight patients switched to open-label caplacizumab (placebo, n = 26; caplacizumab, n = 2); the three others discontinued upon exacerbation. Median time to platelet count response (≥150 x 109 /L) was 3.49 days upon receiving caplacizumab. There were no deaths. During open-label treatment, further exacerbation or a major thromboembolic event (vena cava thrombosis) was experienced by one patient (3.6%) each. Consistent with the double-blind phase, the most frequent treatment-emergent adverse events were catheter site hemorrhage (28.6%), headache (21.4%), and epistaxis (17.9%). CONCLUSIONS These results suggest that caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a disease exacerbation during double-blind treatment in HERCULES

Nitrogen fertilization and its effect on production and Diatraea saccharalis Fab. attack on sugarcane

Nitrogen fertilization is essential to raise sugarcane yield in soils deficient in N. The objective of this study was to evaluate the effect of nitrogen application in production and borer attack on sugarcane. The experiment was conducted at Escobar District, State of Paraguarí, Paraguay. Three sugarcane growing seasons were evaluated during 2011-2013. The experimental design was randomized blocks with seven treatments and three repetitions, with annual application of increasing of nitrogen (0, 30, 60, 90, 120, 150 and 180 kg ha-1). At 360 days of each crop cycle, harvest was performed with the following assessments: industrial plant height, number of internodes per plant, infestation intensity index and yield. The nitrogen rate of maximum technical efficiency and maximum economic efficiency was determined. Statistical analysis of variance, means comparison and regression were performed. Nitrogen fertilization did not affect plant height and number of internodes, but increased yield and borer attack. For every kg ha-1 of nitrogen applied 0.25 t ha-1 of yield is added, and 0.27 % of infestation intensity index increase is obtained. The rate of maximum technical efficiency was 157,4 kg N ha-1 for a yield of 73,6 t ha-1, and the rate of maximum economic efficiency was 136.5 kg N ha-1 for a yield of 88,2 t ha-1

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase statistical power for assessing treatment differences in efficacy and safety outcomes. Caplacizumab was associated with a significant reduction in the number of deaths (0 vs 4; P < .05) and a significantly lower incidence of refractory TTP (0 vs 8; P < .05) vs placebo during the treatment period. Consistent with the individual trials, treatment with caplacizumab resulted in a faster time to platelet count response (hazard ratio, 1.65; P < .001), a 72.6% reduction in the proportion of patients with the composite end point of TTP-related death, TTP exacerbation, or occurrence of at least 1 treatment-emergent major thromboembolic event during the treatment period (13.0% vs 47.3%; P < .001), and a 33.3% reduction in the median number of therapeutic plasma exchange days (5.0 vs 7.5 days) vs placebo. No new safety signals were identified; mild mucocutaneous bleeding was the main safety finding. This integrated analysis provided new evidence that caplacizumab prevents mortality and refractory disease in acquired TTP and strengthened individual trial findings, with a confirmed favorable safety and tolerability profile. These trials were registered at www.clinicaltrials.gov as #NCT01151423 and #NCT02553317

Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.

INTRODUCTION Caplacizumab demonstrated efficacy and safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in the Phase 3 HERCULES trial. However, data on long-term outcomes following caplacizumab treatment are limited. OBJECTIVES The post-HERCULES trial (NCT02878603) evaluated long-term outcomes of patients with iTTP treated with caplacizumab in HERCULES and safety and efficacy of repeated caplacizumab use. PATIENTS/METHODS Over 3 years' follow-up, patients could receive open-label caplacizumab with therapeutic plasma exchange (TPE) and immunosuppressive therapy (IST) in case of recurrence. Adverse events (AEs) were assessed during the overall study period (intention-to-observe [ITO] population) and during recurrences (recurrence population). TTP-related events (TTP-related death, recurrence, major thromboembolic events) were assessed in the efficacy ITO population (patients without recurrence during HERCULES or before post-HERCULES). RESULTS Among 104 enrolled patients, incidences of AEs and serious AEs were similar between patients who had received caplacizumab+TPE+IST during HERCULES (n=75) and those treated with placebo+TPE+IST (placebo; n=29). TTP-related events occurred in 8% of patients (4/49) randomized to caplacizumab during HERCULES versus 38% (11/29) randomized to placebo. Nineteen patients had ≥1 recurrence; 13 of these were treated with caplacizumab. First recurrence episode was resolved or resolving for all patients treated with caplacizumab, including 9 patients with repeat caplacizumab use. All second recurrences (6/6) were resolved. Safety profile of caplacizumab for treatment of recurrence was consistent with HERCULES; most bleeding events were non-serious. No major cases of organ dysfunction were observed. CONCLUSIONS Long-term follow-up supports the safety and efficacy of caplacizumab for iTTP and its repeated use for recurrences

Guidelines for vascular anomalies by the Italian Society for the study of Vascular Anomalies (SISAV)

[no abstract available

A Focus Group Study of Self-Management in Patients With Glomerular Disease

IntroductionPatients with glomerular disease experience symptoms that impair their physical and mental health while managing their treatments, diet, appointments and monitoring general and specific indicators of health and their illness. We sought to describe the perspectives of patients and their care partners on self-management in glomerular disease.MethodsWe conducted 16 focus groups involving adult patients with glomerular disease (n&nbsp;= 101) and their care partners (n&nbsp;= 34) in Australia, Hong Kong, the United Kingdom, and United States. Transcripts were analyzed thematically.ResultsWe identified the following 4 themes: empowered in autonomy (gaining confidence through understanding, taking ownership of disease and treatment, learning a positive health approach); overwhelmed by compounding treatment burdens (financially undermined and depleted, demoralized by side effects and harms, frustrated by fragmented and inflexible care, fear of possible drug harms); striving for stability and normalcy (making personal sacrifices, maximizing life participation, attentiveness to bodily signs, avoiding precarious health states, integrating medicines into routines); and necessity of health-sustaining relationships (buoyed by social support, fulfilling meaningful responsibilities, sharing and normalizing experiences, seeking a trusting and respectful alliance).ConclusionPatients with glomerular disease and their care partners value their capacity for autonomy and disease ownership, stability of their health, and relationships that support self-management. Strategies directed at strengthening these factors may increase self-efficacy and improve the care and outcomes for patients with glomerular disease